Article Text

Download PDFPDF
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome
  1. M-A Dragon-Durey1,2,3,4,
  2. C Blanc2,3,4,
  3. F Marliot1,
  4. C Loirat5,
  5. J Blouin1,
  6. C Sautes-Fridman2,3,4,
  7. W H Fridman1,2,3,4,
  8. V Frémeaux-Bacchi1,2,3,4
  1. 1
    Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d’Immunologie Biologique, Paris, France
  2. 2
    Université Paris Descartes, Faculté de médecine, Paris, France
  3. 3
    Unité INSERM UMRS 872, Centre de Recherche des Cordeliers, team 13, Paris, France
  4. 4
    Université Pierre et Marie Curie, Paris, France
  5. 5
    Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Service de Néphrologie, Université Paris 7, Paris, France
  1. Dr M-A Dragon-Durey, Service d’Immunologie Biologique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75 015 Paris, France; marie-agnes.durey{at}


Background: Deletion of the complement factor H related 1 (CFHR1) gene is a consequence of non-allelic homologous recombination and has been reported to be more frequent in atypical haemolytic uraemic syndrome (aHUS) patients than in the normal population. Therefore, it is considered a susceptibility factor for the disease. aHUS is associated with hereditary or acquired abnormalities that lead to uncontrolled alternative pathway complement activation. We tested the CFHR1 deletion for association with aHUS in a population of French aHUS cases and controls. Furthermore, we examined the effect of the deletion in the context of known aHUS risk factors.

Methods and results: 177 aHUS patients and 70 healthy donors were studied. The number of CFHR1 alleles was quantified by multiplex ligation dependant probe amplification (MLPA). The frequency of the deleted allele was significantly higher in aHUS patients than in controls (22.7% vs 8.2%, p<0.001). The highest frequency was in the subgroup of patients exhibiting anti-factor H (FH) autoantibodies (92.9%, p<0.0001 vs controls) and in the group of patients exhibiting a factor I (CFI) gene mutation (31.8%, p<0.001 vs controls). The CFHR1 deletion was not significantly more frequent in the cohort of aHUS patients when patients with anti-FH IgG or CFI mutation were excluded.

Conclusions: The high frequency of CFHR1 deletion in aHUS patients is restricted to the subgroups of patients presenting with anti-FH autoantibodies or, to a lesser degree, CFI mutation. These results suggest that the CFHR1 deletion plays a secondary role in susceptibility to aHUS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This work was supported in part by grants from the Direction de la Recherche Clinique (DRC) of the Assistance Publique-Hôpitaux de Paris (APHP) (PHRC AOM05130; AOM08198; CIRC 06037) and from GIS-Institut des maladies rares (Maladies Rares et Anomalies de structure du génome).

  • Competing interests: None.

  • Patient consent: Obtained.